News Center
-
%20%E6%8B%B7%E8%B4%9D(1).png)
Spotlight on First-Line Treatment for Liver Cancer! Anlotinib's Tenth Indication Approved, Offering New Hope for Advanced-Stage Patients in Combination with Penpulimab
On December 25, Sino Biopharmaceutical Limited (1177.HK) received a drug registration certificate from the National Medical Products Administration (NMPA) for the tenth indication of its Class 1 innovative drug, Anlotinib Hydrochloride Capsules (Fukewei®).View -
Sino Biopharmaceutical Limited Wins TVB ESG Social Innovation Science and Technology Award, Carbon Neutrality and Climate Governance Actions Receive Professional Recognition
On December 19, at the "2025 TVB Environmental, Social, and Governance (ESG) Awards Presentation Ceremony" held in Hong Kong, organized by TVB and co-organized by the Hong Kong Productivity Council, Sino Biopharmaceutical Limited (1177.HK) was honored with the "ESG Social Innovation Science and Technology Award" for its innovative practices in carbon neutrality strategy and climate risk governance.View -
"2025 Science and Technology + New Quality Productive Forces Summit" Held in Hong Kong, Attended by Ms. Cheng Cheung Ling and Mr. Eric Tse Who Delivered Speeches
On December 16, the "2025 Science and Technology + New Quality Productive Forces Summit", organized by the Hong Kong China Friendship Association, was held in Hong Kong.View -
Sino Biopharm Donates HK$10 Million in Cash and Medicine for Emergency Relief of Tai Po Fire in Hong Kong
On November 26, a sudden fire broke out at Wang Fuk Court in Tai Po District, New Territories, Hong Kong, drawing concern from across the nation.View
Science for a healthier world
